Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dr. Sulaiman Al Habib Medical Services Group Company (4013.SR)
Riyadh, Riyadh Province, SA
Headquartered in Riyadh, Saudi Arabia, Dr. Sulaiman Al Habib Medical Services Group Company, established in 1993, specializes in the development, management, and operation of a wide spectrum of healthcare facilities across the Kingdom. Its extensive portfolio encompasses general and specialized hospitals, various medical complexes, outpatient surgical centers, and pharmaceutical facilities. The group operates hospitals focusing on specific areas such as maternity services, orthopedics, and spinal surgeries. Furthermore, it oversees specialized clinics for dermatology, plastic surgery, ophthalmology, obesity treatment, and fertility, complemented by its network of pharmacies. Beyond direct patient care, the company provides home medical services, advanced laboratory diagnostics, technology and information system support, facility upkeep, medical equipment maintenance, and telemedicine solutions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.94% | -0.22% | -11.00% | -14.03% | -15.72% | -13.42% | -17.59% | -21.38% | +49.33% | +304.55% | +304.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 3 | -1 |
| Sell | 2 | +1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+22.4% ★ Q1'26: +8.8% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+3.8% Q1'26: -9.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+13.8% Q1'26: +14.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+19.3% ★ Q1'26: +17.1% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+16.9% ★ Q1'26: +14.4% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.81× Q1'26: 2.97× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 9 Rev. Ana. 8 EPS Ana. |
Dec 2028 3 Rev. Ana. 7 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.86B
est: 5.82B (+0.8%)
|
7.25B
est: 7.24B (+0.1%)
|
8.31B
est: 8.21B (+1.3%)
|
9.51B
est: 10.02B (-5.1%)
|
11.20B
est: 11.15B (+0.5%)
|
13.71B
est: 13.69B (+0.1%)
|
15.69B
15.55B – 15.93B
+14.6% YoY
|
17.54B
16.95B – 18.22B
+11.8% YoY
|
19.26B
18.83B – 19.79B
+9.8% YoY
|
20.64B
20.18B – 21.21B
+7.2% YoY
|
21.73B
21.24B – 22.32B
+5.2% YoY
|
| EBITDA |
1.50B
est: 1.52B (-1.4%)
|
1.86B
est: 1.89B (-1.8%)
|
2.15B
est: 2.14B (+0.2%)
|
2.55B
est: 2.59B (-1.4%)
|
2.99B
est: 2.88B (+3.9%)
|
3.31B
est: 3.54B (-6.4%)
|
4.05B
4.02B – 4.11B
+14.6% YoY
|
4.53B
4.38B – 4.71B
+11.8% YoY
|
4.98B
4.86B – 5.11B
+9.8% YoY
|
5.33B
5.21B – 5.48B
+7.2% YoY
|
5.61B
5.49B – 5.77B
+5.2% YoY
|
| EBIT |
1.18B
est: 1.28B (-8.1%)
|
1.54B
est: 1.59B (-3.4%)
|
1.85B
est: 1.81B (+2.2%)
|
2.24B
est: 2.19B (+2.4%)
|
2.58B
est: 2.43B (+5.9%)
|
2.64B
est: 2.99B (-11.7%)
|
3.43B
3.39B – 3.48B
+14.6% YoY
|
3.83B
3.70B – 3.98B
+11.8% YoY
|
4.21B
4.11B – 4.32B
+9.8% YoY
|
4.51B
4.41B – 4.63B
+7.2% YoY
|
4.74B
4.64B – 4.87B
+5.2% YoY
|
| Net Income |
1.06B
est: 1.05B (+0.9%)
|
1.38B
est: 1.38B (0.0%)
|
1.65B
est: 1.62B (+1.8%)
|
2.05B
est: 2.18B (-6.0%)
|
2.32B
est: 2.28B (+1.4%)
|
2.40B
est: 2.50B (-3.8%)
|
2.75B
2.69B – 2.80B
+10.1% YoY
|
3.73B
2.94B – 3.83B
+35.6% YoY
|
3.67B
3.56B – 3.80B
-1.5% YoY
|
4.07B
3.95B – 4.21B
+10.9% YoY
|
4.56B
4.43B – 4.73B
+12.2% YoY
|
| SGA |
142.09M
est: 126.34M (+12.5%)
|
137.49M
est: 157.35M (-12.6%)
|
182.18M
est: 178.26M (+2.2%)
|
214.01M
est: 219.25M (-2.4%)
|
235.15M
est: 243.76M (-3.5%)
|
342.32M
est: 299.42M (+14.3%)
|
343.17M
340.11M – 348.32M
+14.6% YoY
|
383.73M
370.64M – 398.53M
+11.8% YoY
|
421.28M
411.88M – 432.90M
+9.8% YoY
|
451.54M
441.46M – 463.99M
+7.2% YoY
|
475.17M
464.56M – 488.27M
+5.2% YoY
|
| EPS |
3.02
est: 2.99 (+1.0%)
|
3.93
est: 3.93 (-0.1%)
|
4.72
est: 4.63 (+1.8%)
|
5.85
est: 6.22 (-5.9%)
|
6.61
est: 6.50 (+1.7%)
|
6.86
est: 6.77 (+1.3%)
|
7.88
7.69 – 8.01
+16.4% YoY
|
9.36
8.40 – 10.95
+18.7% YoY
|
10.48
10.18 – 10.86
+12.0% YoY
|
11.62
11.28 – 12.04
+10.9% YoY
|
13.04
12.66 – 13.51
+12.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-03 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-26 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia Capped UCITS ETF IKSD.L | 1.60% | 308.1K | 0.60% |
| 2 | iShares MSCI Saudi Arabia Capped UCITS ETF IKSA.L | 1.60% | 8.27M | 0.60% |
| 3 | Invesco MSCI Saudi Arabia UCITS ETF MSAU.L | 1.60% | 746.4K | 0.50% |
| 4 | iShares MSCI Saudi Arabia ETF KSA | 1.51% | 9.84M | 0.75% |
| 5 | FlexShares Emerging Markets Quality Low Volatility Index Fund QLVE | 0.56% | 94.2K | 0.19% |
| 6 | iShares Edge MSCI EM Minimum Volatility UCITS ETF EMMV.L | 0.40% | 1.96M | 0.40% |
| 7 | iShares MSCI Emerging Markets Min Vol Factor ETF EEMV | 0.40% | 14.40M | 0.25% |
| 8 | iShares MSCI EM Consumer Growth UCITS ETF CEMG.L | 0.22% | 94.5K | 0.60% |
| 9 | BMO Low Volatility Emerging Markets Equity ETF ZLE.TO | 0.20% | 145.0K | 0.51% |
| 10 | UBS MSCI EM Socially Responsible UCITS ETF USD dis UC79.L | 0.17% | 6.14M | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hesham Sulaiman-Abdulaziz Al-Habib | Chief of Business Development & Strategy and Executive Director | 230.0K | male |
| Faisal Bin Abdullah Ali Al Nassar | Group Chief Financial Officer, Executive Director & Chief Executive Officer of the Group | 230.0K | male |
| Sulaiman Bin Abdulaziz Al Habib | Founder & Non-Executive Chairman | 172.0K | — |
| Awad Abdullah Al-Omari | Chief Medical Officer | — | male |
| Saud Abdulaziz Saad Al Arifi | Group General Counsel & Secretary of the Board | — | male |
| Sulaiman Abdul Aziz Sulaiman Al Majed | Senior Vice President of Medical Affairs | — | — |
| Abdullah Sulaiman Al Herbish | Senior VP of Physicians Affairs & Director | — | — |
| Vimal Subramanian | Head of Internal Audit Department | — | male |
| Abdulwahab Abdullah Mohammed Al Abdulwahab | Chief Operating Officer | — | — |
| Ahmed Babatin | Chief People Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4013.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
